Integral developing NanoM™ platform for extended release, preservative-free, and self-administered treatment of glaucoma and inflammation post-cataract surgery.

BEDFORD, MASSACHUSETTS, USA, May 28, 2016 /EINPresswire.com/ -- BEDFORD, MASSACHUSETTS, USA, May 28, 2016 -- Integral BioSystems LLC, Boston area drug development CRO specializing in pharmaceutical formulation development, will be presenting its ophthalmic pipeline based on its innovative, NanoM™ platform at the 9th Massachusetts Life Sciences Innovation (MALSI) Day on June 2, 2016 at Harvard Club of Boston, 374 Commonwealth Avenue, Boston, MA.

The company’s innovative, NanoM-based pipeline will be presented by Integral BioSystems CEO and President, Shikha Barman, Ph.D. The platform, initially being developed to treat disorders of the ocular surface and anterior chamber is a biodegradable, polymeric, mucoadhesive insert that contains medication that is released over an extended period of time, depending on the clinical need. Ocular surface disorders are chronic or acute, some examples of which are glaucoma, blepharitis, corneal injuries, contact lens-induced bacterial or fungal keratitis, uveitis, conjunctivitis, infections and general inflammation. If left untreated, these disorders may lead to vision impairment.

Disorders of the ocular surface are normally treated by eye-drops, which are rapidly cleared by naso-lacrimal drainage. This requires multiple eye-drop regimens daily to achieve a therapeutic effect, and frequently leads to missed dosing resulting in ineffective treatment of the targeted disease. Additionally, prolonged use of preservatives in dose forms used to treat chronic disorders can cause damage to ocular tissues. The NanoM ocular insert is preservative-free and placed under the lower eyelid and can be modulated to release medication for days to months. Unlike competitor sustained release products, NanoM is self-administered. The technology is early-stage, and is currently in development for the treatment of glaucoma and prevention/treatment of inflammation post-cataract surgery. Once clinically validated, this innovative platform can be developed to treat other ocular disorders, as first-in-its-class, self-administered, sustained release drug products.

This technology has already gained considerable traction with US and international companies, as well as the NIH, which has awarded a Phase I SBIR Grant to further the product’s development. Integral has filed requisite patent applications and is actively developing the platform further to include multiple routes and multiple indications. “This technology will satisfy a long held clinical need and has the potential to be transformative and paradigm-changing, by replacing eye-drops for sustained release therapy requirements”, states Shikha Barman, CEO and inventor of the NanoM platform.

Integral BioSystems seeks investment by interested parties, to develop the platform. A new Company (“NewCo”) is planned as part of a developmental partnership, utilizing Integral BioSystems’ facilities and expertise in formulation and analytical development to develop and ready each product for the platform.
At MALSI, Integral BioSystems will present the innovation at the Innovator’s Workshop. Additionally, the company will also host a booth to showcase its drug development services as a CRO.

About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

Dave Karasic
Integral BioSystems, LLC
617-820-8483
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.